APA (7th ed.) Citation

HJ, X., HQ, Y., J, Z., L, F., D, W., XT, L., & CM, X. (2023). Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice. Military Medical Research, 10(1), 68. https://doi.org/10.1186/s40779-023-00501-8

Chicago Style (17th ed.) Citation

HJ, Xiong, Yu HQ, Zhang J, Fang L, Wu D, Lin XT, and Xie CM. "Elevated FBXL6 Activates Both Wild-type KRAS and Mutant KRASG12D and Drives HCC Tumorigenesis via the ERK/mTOR/PRELID2/ROS Axis in Mice." Military Medical Research 10, no. 1 (2023): 68. https://doi.org/10.1186/s40779-023-00501-8.

MLA (9th ed.) Citation

HJ, Xiong, et al. "Elevated FBXL6 Activates Both Wild-type KRAS and Mutant KRASG12D and Drives HCC Tumorigenesis via the ERK/mTOR/PRELID2/ROS Axis in Mice." Military Medical Research, vol. 10, no. 1, 2023, p. 68, https://doi.org/10.1186/s40779-023-00501-8.